Did NiSource’s (NI) Hybrid Funding and Data Center Push Just Recast Its Long-Term Investment Narrative?
NiSource Inc NI | 0.00 |
- Earlier this month, NiSource Inc. completed a US$750,000,000 fixed-to-floating rate junior subordinated unsecured notes offering due April 15, 2057, while also reporting softer second-quarter earnings and the board declared a US$0.30 per-share common dividend payable November 20, 2026.
- Alongside these actions, management reaffirmed its 2026 adjusted EPS guidance and highlighted advancing regulatory approvals and sizable prospective data center load, underscoring the importance of long-term infrastructure investment and demand growth in its utility footprint.
- We’ll now examine how the reaffirmed 2026 earnings guidance amid expanding data center negotiations may influence NiSource’s existing investment narrative.
The future of work is here. Discover the 37 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
NiSource Investment Narrative Recap
To own NiSource, you have to believe in regulated utility earnings backed by long-term infrastructure spending and growing large-load demand from data centers, while accepting meaningful capital needs and regulatory exposure. The recent US$750,000,000 junior subordinated notes, softer second quarter earnings, and reaffirmed 2026 EPS guidance do not materially change the near term catalyst around data center load growth, but they do reinforce the key risk of sustained balance sheet pressure from heavy investment.
The August fixed to floating rate junior subordinated unsecured notes offering is most relevant here, because it directly ties into how NiSource funds its US$19.4 billion five year capital plan and data center projects. For investors watching catalysts like expanded data center agreements and regulatory approvals, this new layer of junior debt highlights how dependent the equity story is on constructive rate recovery and timely cost pass through to maintain earnings and support ongoing dividends.
Yet while the data center opportunity is appealing, investors should be aware that NiSource’s sizeable, ongoing capital expenditure requirements could...
NiSource’s narrative projects $8.4 billion revenue and $1.3 billion earnings by 2029. This requires 6.8% yearly revenue growth and about a $0.4 billion earnings increase from $906.0 million today.
Uncover how NiSource's forecasts yield a $50.03 fair value, a 18% upside to its current price.
Exploring Other Perspectives
Three fair value estimates from the Simply Wall St Community span roughly US$36 to US$50 per share, showing how far apart individual views can be. Against that backdrop, the heavy capital expenditure program funded in part by junior subordinated debt may leave some investors more focused on how regulatory outcomes and financing terms could shape future returns, so it can be useful to compare several independent assessments before forming a view.
Explore 3 other fair value estimates on NiSource - why the stock might be worth 15% less than the current price!
The Verdict Is Yours
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your NiSource research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
- Our free NiSource research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate NiSource's overall financial health at a glance.
Curious About Other Options?
Every day counts. These free picks are already gaining attention. See them before the crowd does:
- Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
- The latest GPUs need a type of rare earth metal called Neodymium and there are only 28 companies in the world exploring or producing it. Find the list for free.
- AI is about to change healthcare. These 44 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
